Payment overview · 2025
General Payments
$1,596.21
52 reported records · 15 companies
Healthcare provider profile · identity verified
Hao Ngoc Thai, MD
Allopathic & Osteopathic Physicians|Family Medicine · HIGHLAND, CA · NPI 1194058255
Verified facts
What the public records show
CMS Open Payments records show Hao Ngoc Thai, MD received $1,596.21 in general payments during 2025 across 52 reported records.
Amgen Inc. accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Linzess, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Lumigan by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 333 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 333 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $646.36 | 40.5% | 16 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $197.49 | 12.4% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.93 | 9.6% | 6 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $129.17 | 8.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $91.83 | 5.8% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $83.70 | 5.2% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $60.87 | 3.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.83 | 3.2% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $44.69 | 2.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.10 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.33 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.31 | 1.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $21.56 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.32 | 1.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.72 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,596.21 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $478.48 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $205.76 | 8 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $197.49 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $167.88 | 5 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $129.17 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $129.17 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $91.83 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $90.65 | 8 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $83.70 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $60.87 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $44.69 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 51 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 108 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 333 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 207 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
207 | 48 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
37 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
333 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
333 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
108 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 899 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 696 | 152 |
| Losartan Potassium | Losartan Potassium | 631 | 138 |
| Gabapentin | Gabapentin | 484 | 98 |
| Metformin Hcl | Metformin Hcl | 345 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 343 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 336 | 62 |
| Jardiance | Empagliflozin | 333 | 48 |
| Celecoxib | Celecoxib | 331 | 97 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 263 | 97 |
| Donepezil Hcl | Donepezil Hcl | 232 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 228 | 78 |
| Myrbetriq | Mirabegron | 222 | 30 |
| Finasteride | Finasteride | 216 | 27 |
| Linzess | Linaclotide | 207 | 48 |
| Metformin Hcl Er | Metformin Hcl | 202 | 50 |
| Azithromycin | Azithromycin | 200 | 154 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 58 |
| Vascepa | Icosapent Ethyl | 182 | 36 |
| Mirtazapine | Mirtazapine | 181 | 38 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 178 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 176 | 56 |
| Hydralazine Hcl | Hydralazine Hcl | 168 | 26 |
| Atenolol | Atenolol | 167 | 30 |
| Omeprazole | Omeprazole | 163 | 44 |
| Pioglitazone Hcl | Pioglitazone Hcl | 154 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 44 |
| Meloxicam | Meloxicam | 148 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 140 | 24 |
| Tradjenta | Linagliptin | 140 | suppressed |
| Famotidine | Famotidine | 139 | 41 |
| Trazodone Hcl | Trazodone Hcl | 134 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 37 |
| Megestrol Acetate | Megestrol Acetate | 119 | 37 |
| Lidocaine | Lidocaine | 117 | 22 |
| Cyclosporine | Cyclosporine | 115 | 25 |
| Glipizide Er | Glipizide | 115 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 113 | 25 |
| Dexlansoprazole Dr | Dexlansoprazole | 111 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | suppressed |
| Gemtesa | Vibegron | 108 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 103 | 49 |
| Lovastatin | Lovastatin | 94 | 19 |
| Ibuprofen | Ibuprofen | 91 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 18 |
| Memantine Hcl | Memantine Hcl | 90 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 87 | 18 |
| Carvedilol | Carvedilol | 86 | 16 |
| Meclizine Hcl | Meclizine Hcl | 79 | 39 |
| Lisinopril | Lisinopril | 77 | 12 |
| Clonidine Hcl | Clonidine Hcl | 76 | 36 |
| Montelukast Sodium | Montelukast Sodium | 76 | 19 |
| Potassium Chloride | Potassium Chloride | 76 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 74 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 56 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 62 | 46 |
| Alendronate Sodium | Alendronate Sodium | 61 | 21 |
| Baclofen | Baclofen | 61 | 27 |
| Pregabalin | Pregabalin | 60 | 18 |
| Sucralfate | Sucralfate | 58 | suppressed |
| Gemfibrozil | Gemfibrozil | 57 | suppressed |
| Hydrocortisone | Hydrocortisone | 57 | 16 |
| Zenpep | Lipase/Protease/Amylase | 55 | suppressed |
| Olanzapine | Olanzapine | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 40 |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 52 | 15 |
| Farxiga | Dapagliflozin Propanediol | 51 | 16 |
| Calcitriol | Calcitriol | 50 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 49 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 49 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | 13 |
| Cromolyn Sodium | Cromolyn Sodium | 44 | 15 |
| Diltiazem 12hr Er | Diltiazem Hcl | 44 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 44 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | 11 |
| Furosemide | Furosemide | 43 | 16 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 42 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 40 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 37 | 14 |
| Prolia | Denosumab | 37 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 21 |
| Kerendia | Finerenone | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 14 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 24 |
| Loperamide | Loperamide Hcl | 33 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 12 |
| Restasis | Cyclosporine | 32 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 32 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Prednisone | Prednisone | 31 | 25 |
| Simvastatin | Simvastatin | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lumigan | Bimatoprost | 30 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 26 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Dutasteride | Dutasteride | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Mitigare | Colchicine | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 15 |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 17 | 17 |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | 11 |
| Enulose | Lactulose | 16 | suppressed |
| Epogen | Epoetin Alfa | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | 13 |
| Latanoprost | Latanoprost | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Benzonatate | Benzonatate | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,596.21 · 52 records | Amgen Inc. | ACCRUFER, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, GEMTESA, IBSRELA, JARDIANCE, LINZESS, NEXLETOL, OPSUMIT, OTEZLA, REPATHA, UPTRAVI, XIFAXAN, YUPELRI, ZENPEP | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error